Abstract: Diffuse large B- cell lymphoma(DLBCL)shows obvious heterogeneity in clinical features, gene expression, treatment response, and disease prognosis.R- CHOP(rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)is a standard treatment regimen for DLBCL that no longer meets clinical needs; indeed, several recent successive clinical trials failed to demonstrate the efficacy of cell-of-origin-based R-CHOP+X therapy.Therefore, in-depth studies on molecular genetic abnormalities associated with DLBCL are urgently needed to develop gene mutation-based classification systems that could serve as a basis for monitoring disease progression and developing therapeutic methods and targeted drugs for this condition.The increasing use of gene detection technology for the molecular-pathological diagnosis of tumors also strongly supports the need for in-depth studies on DLBCL genotyping.Therefore, herein, we review the latest published reports on DLBCL genotype classification systems.